Profil
Hong Xin Wang is currently the Chairman & Chief Executive Officer at Shenzhen Academia Capital Management Co., Ltd. Prior to this, he served as an Independent Director at Shenzhen Salubris Pharmaceuticals Co., Ltd. from 2016 to 2020.
He also worked as a Portfolio Manager at Bosera Asset Management Co., Ltd. from 2012 to 2014.
Postes actifs de Hong Xin Wang
| Sociétés | Poste | Début |
|---|---|---|
Shenzhen Academia Capital Management Co., Ltd.
Shenzhen Academia Capital Management Co., Ltd. Investment ManagersFinance Provides investment advice | Directeur Général | - |
Anciens postes connus de Hong Xin Wang
| Sociétés | Poste | Fin |
|---|---|---|
| SHENZHEN SALUBRIS PHARMACEUTICALS CO., LTD. | Directeur/Membre du Conseil | 10/01/2020 |
Bosera Asset Management Co., Ltd.
Bosera Asset Management Co., Ltd. Investment ManagersFinance Bosera AM is an active, value-oriented, long-term manager which invests in equity, fixed-income and money market instruments, with a strong focus on China. Their equity investment emphasizes on fundamental analysis based on internal research on listed companies that exhibit stable business growth, core competencies and growth potential. The firm believes that the stock price on the secondary market will eventually reflects the intrinsic value of the enterprise and in-depth analysis and research is the only way to generate returns and minimize risks. | Gestionnaire de Portefeuille-Actions | - |
Expériences
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Bosera Asset Management Co., Ltd.
Bosera Asset Management Co., Ltd. Investment ManagersFinance Bosera AM is an active, value-oriented, long-term manager which invests in equity, fixed-income and money market instruments, with a strong focus on China. Their equity investment emphasizes on fundamental analysis based on internal research on listed companies that exhibit stable business growth, core competencies and growth potential. The firm believes that the stock price on the secondary market will eventually reflects the intrinsic value of the enterprise and in-depth analysis and research is the only way to generate returns and minimize risks. | Finance |
Shenzhen Salubris Pharmaceuticals Co., Ltd.
Shenzhen Salubris Pharmaceuticals Co., Ltd. Pharmaceuticals: MajorHealth Technology Engages in research & development, production and sale of pharmaceuticals and medical devices | Health Technology |
Shenzhen Academia Capital Management Co., Ltd.
Shenzhen Academia Capital Management Co., Ltd. Investment ManagersFinance Provides investment advice | Finance |
















